Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody, Versus Investigator's Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)
Lymphoma
Lymphoma
Lymphoma
III
Bhaskar, Shakthi
NCT06091254
VICC-DTPCL23483
Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours
Germ Cell (Pediatrics)
Germ Cell (Pediatrics)
Germ Cell (Pediatrics)
III
Borinstein, Scott
NCT02582697
COGAGCT1532
Endoscopic Gastroenterostomy Versus Surgical Gastrojejunostomy for Treatment of Malignant Gastric Outlet Obstruction: A Randomized Controlled Trial
Gastrointestinal
Gastrointestinal
Gastrointestinal
N/A
Yachimski, Patrick
NCT06567691
VICCGI24560
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Kidney (Renal Cell)
Kidney (Renal Cell)
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Kidney (Renal Cell)
III
Rini, Brian
NCT07011719
VICCURO24575
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Not Available
I
Fedorov, Kateryna
NCT06001788
VICC-DTHEM23484P
A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer
Uterine
Uterine
Uterine
III
Brown, Alaina
NCT07198074
NRGGYNGY035
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
Hematologic
Hematologic
Hematologic
III
Dholaria, Bhagirathbhai
NCT03394365
VICCCTT1875
Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response
Pancreatic
Pancreatic
Pancreatic
N/A
Xu, Junzhong
NCT04588025
VICCGI2099
A Phase 1/2, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors
Miscellaneous
Miscellaneous
Miscellaneous
I/II
Heumann, Thatcher
NCT05523947
VICC-DTMDT24023
A Phase II Trial Evaluating Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
Not Available
II
Esbenshade, Adam
NCT06368817
COGACNS2321